Finally, the significant tumour growth delay in tumours in the Th-MYCN mice seen at 24 and 48 hrs after daily treatment with cabozantinib translated into a significant reduction in tumour progression seen over 7 days and a clear survival benefit, highlighting the potential of cabozantinib for the treatment of MYCN-amplified neuroblastoma. The gene discussed is MYCN; the disease is neuroblastoma.